Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al.|The Lancet Diabetes & Endocrinology|2019Cited by 171